|
KMID : 1145520150010020137
|
|
Journal of Radiopharmaceuticals and Molecular Probes
2015 Volume.1 No. 2 p.137 ~ p.144
|
|
|
Biodistribution and PET imaging of [18F]FMISO in mousecolon cancer xenografted mice
|
|
Seelam Sudhakara Reddy
Lee Ji-Youn
Kim Young-Joo
Lee Yun-Sang
Jeong Jae-Min
|
|
|
Abstract
|
|
|
Hypoxia is an important adverse prognostic factor for tumor progression and is a major cause of failure of radiation therapy. In case of short-term hypoxia, the metabolism can recover to normal, but if hypoxia persists, it causes irreversible cell damage and finally leads to death. So a hypoxia marker would be very useful inoncology. In particular, 2-nitroimidazole can be reduced to form a reactive chemical species, which can bind irreversibly to cell components in the absence of sufficient oxygen, thus, the development of radiolabeled nitroimidazole derivatives for the imaging of hypoxia remains an active field of research to improve cancer therapy result. 2-nitroimidazole based hypoxia marker, [18F]FMISO holds promise for the evaluation of tumor hypoxia by Positron emission tomography (PET), at both global and local levels. In the present study, [18F]FMISO was synthesized using an automatic synthesis module with high radiochemical purity (>99%) in 60 min. Immunohistochemical analysis using pimonidazole confirmed the presence of hypoxia in xenografted
CT-26 tumor tissue. A biodistribution study in CT-26 xenografted mice showed that the increased tumor-to-muscle ratio and tumor-to-blood ratios from 10 to 120 min post-injection. In the PET study, [18F]FMISO also showed increased tumor-to-muscle ratios from 10 to 120 min post-injection. In conclusion, this study demonstrates the feasibility and utility of [18F]FMISO for imaging hypoxia in mouse colon cancer model using small animal PET.
|
|
|
KEYWORD
|
|
|
[18F]FMISO, PET, Fluorine-18, Hypoxia, CT-26 mouse colon cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|